Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/1/2025 | $11.00 | Outperform | Raymond James |
| 7/31/2024 | $20.00 | Outperform | Raymond James |
| 7/14/2023 | Overweight | Piper Sandler | |
| 6/30/2023 | $2.00 → $10.00 | Hold → Buy | Stifel |
| 6/28/2023 | $11.00 | Neutral → Buy | H.C. Wainwright |
| 6/27/2023 | $10.00 | Neutral → Outperform | Wedbush |
| 3/29/2022 | Outperform → Neutral | Wedbush | |
| 3/22/2022 | Buy → Neutral | H.C. Wainwright |
Raymond James resumed coverage of Black Diamond Therapeutics with a rating of Outperform and set a new price target of $11.00
Raymond James initiated coverage of Black Diamond Therapeutics with a rating of Outperform and set a new price target of $20.00
Piper Sandler initiated coverage of Black Diamond Therapeutics with a rating of Overweight
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
10-Q - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership opportunities to advance pivotal development of silevertinib in NSCLC and GBMPlan to meet with FDA regarding 1L NSCLC development path in 1H 2026, when PFS data becomes availableCash, cash equivalents, and investments of $142.8 million as of June 30, 2025; expected to be sufficient to fund operations into Q4 of 2027 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target famili
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day. Presentation details are as follows: 4:20-4:50pm ET on Wednesday, June 4 The Webcast will be available at the start of the presentation on the investor relations section of the Compan
Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025Cash, cash equivalents, and investments of $152.4 million as of March 31, 2025; expected to be sufficient to fund operations into Q4 of 2027 CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 3
SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
SC 13G - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncolog
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the fir
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR mutations Confirmed radiographic partial response by RECIST 1.1 achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in subgroup with measurable disease, who underwent post baseline tumor assessment by RECIST1.1; one additional patient demonstrated unconfirmed PR awaiting confirmation, while the remaining six patients had stable diseaseExpansion cohorts expected to commence i